金吾财讯 | 华润医药(03320)公告，截至2024年12月31日止年度，公司权益持有人应占年内溢利33.51亿元（人民币，下同），同比减少13.06%，每股基本盈利0.53元。董事会建议派付末期股息每股0.052元。期内，收益2576.73亿元，同比增长5.3%。2024年制药、医药分销、药品零售及其他三个主要业务分部的收益占比分别为16.1%、80.0%以及3.9%。期内，制药业务实现分部收益463.24亿元，同比增长6.6%，中药、化学药及生物药业务板块收入实现增长。制药业务毛利率为59.4%，较上年同期上升0.3个百分点，主要因为产品结构优化，以及工艺改进、生产环节效率提升。其中，中药业务录得收益242.33亿元，较上年同期增长12.2%。期内，医药分销业务实现分部收益2132.37亿元，同比增长5.5%。分销业务毛利率为5.9%，与上年同期持平。集团医药零售业务录得收益101.04亿元，同比增长5.5%，主要因为高值药品直送(DTP)业务收入增速较快。报告期内，集团的DTP业务实现收益约69亿元，同比增长约17%。零售业务毛利率为6.2%，较上年同期下降1.4个百分点，主要因为利润率水平较低的DTP业务收入比重增加。期内，毛利为406.89亿元，同比增长6.13%。整体毛利率为15.8%，与2023年毛利率15.7%相比提高0.1个百分点，主要受益于报告期内制药业务毛利率水平提升拉动。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.